B-Cell Lymphoma

Oncology
17
Pipeline Programs
16
Companies
20
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
5
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
360%
ADC
120%
Cell Therapy
120%
+ 12 programs with unclassified modality

Competitive Landscape

16 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
2 programs
2
GlofitamabPhase 2Monoclonal Antibody1 trial
rituximabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06670105Withdrawn0Est. Jan 2032
NCT00895661Completed40Est. Aug 2015
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
Axicabtagene CiloleucelPhase 2Cell Therapy1 trial
Active Trials
NCT03761056Completed42Est. Oct 2023
CT
1 program
1
TQB3702 tablets+Chemotherapy regimenPhase 21 trial
Active Trials
NCT06566586RecruitingEst. Dec 2027
Bayer
BayerLEVERKUSEN, Germany
1 program
1
90Y-ibritumomabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT00761384Completed7Est. Jan 2016
BioInvent International
1 program
1
BI-1206 single agent dose escalation phasePhase 1/21 trial
Active Trials
NCT02933320Completed14Est. Mar 2020
CRISPR Therapeutics
1 program
1
CTX112Phase 1/21 trial
Active Trials
NCT05643742Recruiting120Est. Feb 2030
Dynavax Technologies
Dynavax TechnologiesCA - Emeryville
1 program
1
SD-101Phase 1/21 trial
Active Trials
NCT02266147Terminated29Est. Apr 2017
UP
UCB PharmaBelgium - Brussels
1 program
1
inotuzumab ozogamicinPhase 1/2ADC1 trial
Active Trials
NCT00299494Completed119Est. Jun 2014
Takeda
TakedaTOKYO, Japan
1 program
1
19Phase 14 trials
Active Trials
NCT05757700Active Not Recruiting30Est. Feb 2026
NCT04892888Withdrawn0Est. Apr 2023
NCT04422509Completed43Est. Apr 2021
+1 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ABBV-623Phase 11 trial
Active Trials
NCT04804254Terminated5Est. Jan 2023
Astellas
AstellasChina - Shenyang
1 program
1
ASP2802Phase 11 trial
Active Trials
NCT06248086Terminated1Est. Dec 2024
Acepodia
AcepodiaCA - Alameda
1 program
1
CyclophosphamidePhase 11 trial
Active Trials
NCT05653271RecruitingEst. Sep 2027
Qihan Biotech
Qihan BiotechChina - Hangzhou
1 program
1
QN-019aPhase 11 trial
Active Trials
NCT05379647UnknownEst. Dec 2024
Sutro Biopharma
Sutro BiopharmaSOUTH SAN FRANCISCO, CA
1 program
1
STRO-001Phase 11 trial
Active Trials
NCT03424603Completed70Est. Mar 2024
TG Therapeutics
TG TherapeuticsNEW YORK, NY
1 program
1
TG-1801Phase 11 trial
Active Trials
NCT03804996Completed50Est. Feb 2024
Karyopharm Therapeutics
1 program
1
selinexorPhase 11 trial
Active Trials
NCT02741388CompletedEst. Sep 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
GenentechGlofitamab
Chia Tai TianQing Pharmaceutical GroupTQB3702 tablets+Chemotherapy regimen
Gilead SciencesAxicabtagene Ciloleucel
Genentechrituximab
CRISPR TherapeuticsCTX112
Takeda19
BioInvent InternationalBI-1206 single agent dose escalation phase
Dynavax TechnologiesSD-101
Bayer90Y-ibritumomab
UCB Pharmainotuzumab ozogamicin
AstellasASP2802
Takeda19
AcepodiaCyclophosphamide
Qihan BiotechQN-019a
AbbVieABBV-623

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 600 patients across 20 trials

NCT06670105GenentechGlofitamab

A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Start: Jun 2025Est. completion: Jan 20320
Phase 2Withdrawn
NCT06566586Chia Tai TianQing Pharmaceutical GroupTQB3702 tablets+Chemotherapy regimen

A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma

Start: Nov 2024Est. completion: Dec 2027
Phase 2Recruiting
NCT03761056Gilead SciencesAxicabtagene Ciloleucel

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

Start: Jan 2019Est. completion: Oct 202342 patients
Phase 2Completed
NCT00895661Genentechrituximab

High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas

Start: Jul 2009Est. completion: Aug 201540 patients
Phase 2Completed
NCT05643742CRISPR TherapeuticsCTX112

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Start: Mar 2023Est. completion: Feb 2030120 patients
Phase 1/2Recruiting
NCT04422509Takeda19

Lanadelumab for Treatment of COVID-19 Disease

Start: Oct 2020Est. completion: Apr 202143 patients
Phase 1/2Completed
NCT02933320BioInvent InternationalBI-1206 single agent dose escalation phase

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

Start: Oct 2016Est. completion: Mar 202014 patients
Phase 1/2Completed
NCT02266147Dynavax TechnologiesSD-101

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Start: Oct 2014Est. completion: Apr 201729 patients
Phase 1/2Terminated
NCT00761384Bayer90Y-ibritumomab

High Dose, Absorbed Dose Adjusted 90Y-ibritumomab With Peripheral Blood Stem Cells (PBSC) Support in B-cell Lymphoma

Start: Apr 2008Est. completion: Jan 20167 patients
Phase 1/2Completed
NCT00299494UCB Pharmainotuzumab ozogamicin

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Start: May 2006Est. completion: Jun 2014119 patients
Phase 1/2Completed
NCT06248086AstellasASP2802

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

Start: Sep 2024Est. completion: Dec 20241 patients
Phase 1Terminated
NCT05757700Takeda19

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

Start: Feb 2023Est. completion: Feb 202630 patients
Phase 1Active Not Recruiting
NCT05653271AcepodiaCyclophosphamide

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Start: Jan 2023Est. completion: Sep 2027
Phase 1Recruiting
NCT05379647Qihan BiotechQN-019a

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

Start: Nov 2021Est. completion: Dec 2024
Phase 1Unknown
NCT04804254AbbVieABBV-623

Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers

Start: Apr 2021Est. completion: Jan 20235 patients
Phase 1Terminated
NCT04464200Takeda19

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Start: Jul 2020Est. completion: Jul 202630 patients
Phase 1Active Not Recruiting
NCT03804996TG TherapeuticsTG-1801

Study of TG-1801 in Subjects With B-Cell Lymphoma

Start: Mar 2019Est. completion: Feb 202450 patients
Phase 1Completed
NCT03424603Sutro BiopharmaSTRO-001

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Start: Feb 2018Est. completion: Mar 202470 patients
Phase 1Completed
NCT02741388Karyopharm Therapeuticsselinexor

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

Start: Oct 2016Est. completion: Sep 2021
Phase 1Completed
NCT04892888Takeda19

Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms

Start: Aug 2022Est. completion: Apr 20230
N/AWithdrawn

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3m ago

Office Administrator

SystImmune
3m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
13m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
17m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
17m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 600 patients
16 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)